Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by equities researchers at Stifel Nicolaus from ...
Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into ...
Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.
Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...
While the spotlight has been on the SEC’s legal battles and XRP’s market movements, savvy investors have been securing their ...
As investors seek high-growth opportunities in the evolving crypto market, projects with strong fundamentals and real-world ...
Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...
Wall Street Pepe Completes Presale, Forecasting 10x Gains Wall Street Pepe ($WEPE) has wrapped up its presale, with ...